Pharma

Your Article Summary

See Latest Articles

Array BioPharma Advances Its Lead MEK Inhibitor into Cancer
Array BioPharma, 08/14/09

Array BioPharma Inc. announced the filing of an investigational new drug application with the U.S. Food and Drug Administration to initiate a Phase 1 clinical trial in cancer patients with its most advanced wholly owned MEK inhibitor, ARRY–162. Recent research confirms that the MEK pathway acts as a central axis in the proliferation of different tumors including melanoma, non–small cell lung, head/neck and pancreatic cancers. Array plans to simultaneously develop ARRY–162 for the treatment of both cancer and inflammatory disease.

Today in Regulatory Issues...keeping you current

Receive free subspecialty "5-minute updates" via email

Advisory Committee briefing materials for CRESTOR sNDA available on US FDA web site
AstraZeneca, 12/15/09

Sixteen Fired for Records Snooping
HealthDataManagement, 12/09/09

Watson Files FDA Application for Generic Rozerem
Watson Pharmaceuticals, 12/07/09

 See all of Regulatory Issues